跳至主要内容
临床试验/NCT00909051
NCT00909051已完成不适用

Diabetes Treatment by Glucobay® With a Special Therapeutic View to Chosen Patient Groups

Bayer0 个研究点目标入组 15,729 人开始时间: 2009年3月24日最近更新:
适应症
干预措施
相关药物

试验速览

阶段
不适用
状态
已完成
发起方
Bayer
入组人数
15,729
主要终点
Data collection on patients weight and waist circumference, fasting blood glucose, postprandial blood glucose (2h), HbA1C; exploratory analysis according to patient groups (concomitant cardiovascular disease groups, BMI)

研究概览

简要总结

Evaluation of safety and effectiveness of Glucobay® under daily-life treatment conditions in a large sample of patients.

研究设计

研究类型
Observational
观察模型
Cohort
时间视角
Prospective

入排标准

年龄范围
18 Years 至 —(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • Patients with untreated or pretreated diabetes mellitus or patients for which acarbose is indicated and without acarbose treatment within the last three months before study inclusion. The decision for treatment type and duration is taken by the investigator and is made before inclusion into the study.

排除标准

  • Exclusion criteria must be read in conjunction with the local product information.

研究组 & 干预措施

Group 1

干预措施: Acarbose (Glucobay, BAYG5421) (Drug)

结局指标

主要结局

Data collection on patients weight and waist circumference, fasting blood glucose, postprandial blood glucose (2h), HbA1C; exploratory analysis according to patient groups (concomitant cardiovascular disease groups, BMI)

时间窗: During observation period of three months

次要结局

未报告次要终点

研究者

发起方
Bayer
申办方类型
Industry
责任方
Sponsor

相似试验

GlucoVIP - Diabetes Treatment by Glucobay® With a... | 临床试验